BioSpace takes stock of the psychedelic therapeutics space, which is once again on the cusp of its first FDA approval.
After reviewing Bausch & Lomb’s response to its observations, the FDA questioned whether the company is committed to ...
Sling Therapeutics is advancing the first late-stage oral drug for thyroid eye disease that, if approved, could compete ...
Milford, Massachusetts site event recognizes achievements, strong performance, and growing client base since completion of ...
The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday ...
A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving ...
Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit compliance in ...
Biopharma professionals are among those delaying retirement, with 52% expecting to leave the workforce later than originally ...
As AI becomes more embedded in biotech R&D, companies are competing for professionals who can bridge biology, machine ...
A study published today in JAMA Network Open, led by anesthesiologists at Montefiore Einstein, demonstrates that reducing IV ...
The National Organization for Rare Disorders (NORD®) and the Rosenau Family Research Foundation today launched Rare Research ...
Study assessments include measurements of mutant HTT protein, PMS1 mRNA, and cUHDRS. Enrollment and treatment in the Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results